Asymmetrex’s Plan for Free Stem Cell Counting Is The Feature Story by Superb Crew News

by Asymmetrex

This week, Massachusetts stem cell biotechnology company Asymmetrex was the feature news story by online business and technology news platform Superb Crew. The attraction for the choice of Asymmetrex is the company’s recent announcement of its plan to begin offering free tissue stem cell counting to the stem cell research, stem cell medicine, and pharmaceutical industries.

In its June 22 online post, business and technology news platform Superb Crew reported its feature interview with Dr. James L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company Asymmetrex. Superb Crew decided to highlight Asymmetrex after the company announced on June 16 that starting July 5 it would begin offering free tissue stem cell counting at its company website.

In the interview, Sherley discussed Asymmetrex’s tissue stem cell counting technology with the perspective that it is a very recent development for the industry. He noted that, like many new transformative biotechnologies, it and its value are not yet widely known. The planned free stem cell counting site is a part of Asymmetrex’s greater vision to increase academic and industry awareness of the need for tissue stem cell counting and its value, while at the same time making it readily available for immediate practice.

An earlier podcast series on “Counting Stem Cells” featured on the international stem cell industry networking platform RegMedNet, relates the many benefits of Asymmetrex’s technology for stem cell research, stem cell medicine, tissue stem cell biomanufacturing, pharmaceutical development, and environmental health science. By getting the technology out into use for free, Asymmetrex plans to “ignite a widespread adoption of tissue stem cell counting as [the] new normal” for tissue stem cell research, stem cell medicine, and drug development.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dosage and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies, cell biomanufacturing, and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Read More

Asymmetrex Announces Plans to Provide Free Tissue Stem Cell Counting

by Asymmetrex

Today, June 16, Massachusetts stem cell biotechnology company Asymmetrex announces that it will begin offering free tissue stem cell counting on its company website. Scheduled for opening July 5, Independence Day weekend in the U.S., the company’s counting site will give academic scientists, stem cell medicine physicians, tissue stem cell suppliers, and drug companies a new independence to begin incorporating exact numbers for tissue stem cell fraction and dosage in their research, stem cell treatments, cell manufacturing, and drug evaluations.

The director of stem cell biotechnology company Asymmetrex, Dr. James L. Sherley, M.D., Ph.D., is betting that if the stem cell medicine and pharmaceutical industries have easier access to stem cell counting, they will soon make it a routine part of their practice. So, starting July 5 of this year, Independence Day weekend in the U.S., Asymmetrex is offering free tissue stem cell counting at its website.

Obtaining a free stem cell count will only require entry of simple total cell count data at the company’s website. Counting total cells is a widely used, common practice throughout academic cell science, industrial cell manufacturing, drug development, and clinical medicine. However, counting tissue stem cells is only possible with Asymmetrex’s AlphaSTEM Test™ software technology. Simple cell culture procedures will be provided at the free stem cell count site. By following the simple cell culture and total cell counting procedures, any basic cell culture lab can generate the data needed for Asymmetrex to deliver a tissue stem cell-specific count to them in short order.

Asymmetrex’s tissue stem cell counting technology is a recent development for the industry. So, presently, its value is not widely known. There are many examples where the need for tissue stem cell counting has been ignored for years, because previously there was no way to do it. Counting would improve the design and interpretation of tissue stem cell research. Counting tissue stem cells would allow better optimization of cell and tissue manufacturing processes. Counting would provide better quality control for produced and transported tissue stem cell products. Counting would provide crucial dosages for stem cell treatments and stem cell clinical trials. Counting cord blood stem cells would make leukemia treatments for children more reliable. Counting tissue stem cells would provide inexpensive, early identification of stem cell-toxic drug candidates that would fail later in expensive clinical trials.

The planned free stem cell counting site is a part of Asymmetrex’s campaign to increase academic and industry awareness of the need for tissue stem cell counting and its value. In an earlier podcast series on “Counting Stem Cells” featured on the international stem cell industry networking platform RegMedNet, Director Sherley discusses the benefits of Asymmetrex’s technology for stem cell research, stem cell medicine, tissue stem cell biomanufacturing, pharmaceutical development, and environmental health science. Sherley now expects that, “The new free tissue stem cell counting site will give members of our industry the freedom to rediscover, for themselves, the value of counting.”

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dosage and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies, cell biomanufacturing, and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Read More

Asymmetrex Director Sherley Addresses the Clinical Trial Supply Industry About the Benefits of Stem Cell Counting

by Asymmetrex
May 12, 2020

 

In Arena International’s Clinical Trial Supply 2020 Virtual Experience online conference, Asymmetrex Director James Sherley discussed unique challenges in the supply chain of therapies for stem cell transplantation medicine, gene therapy, and gene-editing therapy that can be readily addressed by greater use of tissue stem cell counting technologies like those developed by Asymmetrex.

In particular, Sherley stressed that certification of the stability of the therapeutic doses of natural and gene-engineered tissue stem cells is essential for elevating the supply of stem-gene clinical trials to greater quality and reliability.
Read More

medRxiv Publishes Asymmetrex Director’s Analysis of a Misread on COVID-19 Spread

by Asymmetrex

Based on interrogation of public coronavirus data, Asymmetrex Director Sherley reports suspicion of a misread on COVID-19 spread

In a preprint posted on medRxiv, Asymmetrex Director James Sherley reports the discovery of surprising relationships between how many positive coronavirus tests are found and how many tests were given.  Everyone recognizes that if no tests were given, there would be no positive tests.  And it is expected that, if there is coronavirus in people in a place, more testing will discover more cases.  But it would be surprising if, after thousands of tests were performed, all countries worldwide – or nationwide in the case of the U.S. – would show numbers of positive tests that were directly related to how many tests were given.  It’s hard to imagine that a point source of virus spread could become so uniformly distributed so soon.  But that is exactly what Director Sherley found when he reviewed WHO and U.S. CDC data that are publicly available.  The correlation is particularly impressive for the U.S., approaching the extreme case of all positive test numbers being due to the test itself and not a rapidly spreading coronavirus.

In addition to his expertise and experience in developing tissue stem cell counting tests, Sherley is trained as an epidemiologist.  His training began in cancer epidemiology for cancer prevention and control at the Fox Chase Cancer Center in Philadelphia.  Thereafter at MIT, in addition to cancer research and stem cell research, he led environmental health science research projects and taught undergraduate courses in epidemiology and biostatistics.  The principles of epidemiology test design and evaluation were a main focus of his teaching.

In his medRxiv preprint, Sherley suggests two other possible explanations, in many cases, for remarkable numbers of positive coronavirus tests.  Either or both explanations may be correct.  One is that current tests being used make mistakes a lot, calling people positive about 10% of the time, when they have no virus infection.  The second is that the virus has not recently spread to the U.S. from the 2019 event in China.  Instead, the virus may have been already present in the U.S. population, with a detectable level in about 10% of people.  Sherley advises that if either of these explanations is a factor in the current picture of the coronavirus crisis, then that picture needs to re-drawn quickly.  He also chides government scientists that they should have performed analyses to rule out these possible factors much earlier.

Read entire piece here.

Read More

SuperbCrew Interviews Asymmetrex CEO James L. Sherley

by Asymmetrex

SuperbCrew, a business news website dedicated to covering innovative companies in the tech and business fields, recently interviewed Asymmetrex CEO James L. Sherley.

Dr. Sherley discusses Asymmetrex’s background, his personal background, and the newly developed algorithms for rapid low cost counting of therapeutic tissue stem cells.

“Together AlphaSTAR and Asymmetrex solve the 6 decades unsolved tissue stem cell counting problem. Our AlphaSTEM Test™ technology can count any type of human tissue stem cell that can be grown in culture.”

Read the full SuperbCrew Q&A here!

Read More

Asymmetrex Announces New Algorithms for Rapid Low Cost Counting of Therapeutic Tissue Stem Cells

by Asymmetrex

Today, at the 6th Annual Perinatal Stem Cell Society Congress in Salt Lake City, Utah, Massachusetts stem cell biotechnology company Asymmetrex will announce its newest advance in technologies for specific counting of tissue stem cells. The company will report the use of its AlphaSTEM Test™ technology to discover the first mathematical algorithms for rapidly calculating the specific number of tissue stem cells from simple cell culture data at low cost.

In September 2016, stem cell biotechnology company Asymmetrex introduced its AlphaSTEM Test™ technology. The AlphaSTEM Test™ is the first, and still only, available technology that provides the cell-specific count or dose of tissue stem cells. Other technologies that attempt to provide information about the number and quality of therapeutic tissue stem cells are unable to distinguish them from more abundant non-stem progenitor cells. Although non-stem progenitor cells can have therapeutic effects, only tissue stem cells can provide long-term cures.

Although needed in academic stem cell research, stem cell biomanufacturing, and stem cell medicine, adoption of the AlphaSTEM Test™ has been limited. James Sherley, M.D., Ph.D., founder and director of Asymmetrex, attributes this initial response to two main factors. “There’s a lot of misinformation in the stem cell industry about the nature of tissue stem cell preparations and how counting stem cells specifically would solve many of the current problems faced by the industry and patients.” To address the need for better knowledge of the properties of tissue stem cells and their preparations, this week the company launched its recently developed podcast series on “Counting Stem Cells” on the international stem cell industry networking platform RegMedNet.

Today at the 6th Annual Congress of the Perinatal Stem Cell Society in Salt Lake City, Utah, Director Sherley will address what he thinks is the second cause of slow adoption of the company’s initial technology. “Our tech is an amazing advance for the stem cell industry, but it takes a lot of time to do – previously several weeks to get an answer – even though an answer available nowhere else; and it’s rather expensive compared to other tests that confound the marketplace.” In his talk today, Sherley says, “Now, …everything will change.”

Using its computational strength, Asymmetrex has discovered mathematical algorithms that allow simple cell count data from a few days of culture to be used to calculate the stem cell-specific count of a sample. The new foundational stem cell algorithms address the need for timely, inexpensive stem cell-specific counting. The members of the Perinatal Stem Cell Society are an ideal audience for this first public report. Transplant therapies for children with leukemias have needed a means to insure sufficient blood stem cells for many years; and tissue stem cells from the umbilical cord are currently a major focus for the development of new stem cell therapies.

Asymmetrex is now accelerating its efforts to identify investors and industry partners who market basic cell counter devices. The company plans to integrate the new algorithms with existing electronic cell counters to develop the first tissue stem cell counters for tissue stem cell research, tissue stem cell biomanufacturing, and stem cell therapies.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Read More

Asymmetrex’s Podcast Series Featured on RegMedNet

by Asymmetrex

RegMedNet highlighted Asymmetrex and its Counting Stem Cells podcast from James Sherley, founder and director of Asymmetrex. The Counting Stem Cells podcast has six episodes outlining current usage of stem cells, the current counting problem, why it matters, the Asymmetrex solution, and a vision for the future.

“We cannot continue to work in the field of stem cell science, stem cell medicine, blindly.” – James Sherley

Check out the article on RegMedNet for a brief summary on the podcasts and more. You can also listen to these podcasts here on our website.

Read More

Asymmetrex Talks with Tech Company News About Introducing Tissue Stem Cell Counting to the Advanced Regenerative Manufacturing Institute (ARMI)

by Asymmetrex

Online news platform Tech Company News caught up with Asymmetrex Director James Sherley to ask him about his expectations for Asymmetrex’s new membership in ARMI.

“Working with our partner AlphaSTAR Corporation, Asymmetrex has solved the first problem. We now offer the first ever technology for specific and accurate counting of any human tissue stem cell type, including blood stem cells, liver stem cells, stem cells derived from fat, and others under evaluation for medical applications. This expertise and technology is what we bring to ARMI BioFabUSA with our new membership.”

Their interview is posted here!

Read More

Advanced Regenerative Manufacturing Institute Highlights New Partnership with Asymmetrex

by Asymmetrex

Recently, Asymmetrex LLC joined forces with a new public-private Manufacturing USA Initiative, the Advanced Regenerative Manufacturing Institute (ARMI). ARMI highlighted Asymmetrex in its New Member Spotlight.

This member spotlight goes into detail about the crucial hurdle regenerative medicine is currently facing — a quantitative discipline for tissue stem cells. Dr. James Sherley speaks to ARMI about just this and how Asymmetrex’s technology will put an end to this:

“Achieving this shift in technical practice and conceptual perspective would immediately address several other hurdles that are more widely acknowledged.  Examples include evaluating the efficacy of stem cell clinical trials with small sample size; developing industry standards for certifying the stability of transported stem cell therapies; defining the potency of stem cell treatments.  The currently limited FDA guidance for human cell, tissue, and cellular and tissue-based products (HCT/P) might also be improved by incorporating a stem cell-specific dose basis,” Sherley explained.

Read the full Member Spotlight here!

Read More